This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Oct 2011

WuXi Pharmaceuticals Acquires Two Chinese Clinical CROs

The two Shanghai-based firms provide services spanning regulatory affairs, Phase I–IV clinical trials management, and clinical trial site management, throughout most of China.

China's R&D outsourcing specialist WuXi Pharmaceuticals has bought two related Shanghai-based contract clinical research development services, MedKey Med-Tech Development and Jiecheng Med-Tech Development.

 

The two acquired firms provide services spanning regulatory affairs, Phase I–IV clinical trials management, and clinical trial site management, throughout most of China.

 

"This acquisition provides WuXi an existing clinical development service capability and infrastructure that WuXi will expand and strengthen to serve our customers’ growing clinical development needs in the fast-growing Chinese healthcare market,” comments Ge Li, Ph.D., chairman and CEO.

 

WuXi Pharmaceut

Related News